140 related articles for article (PubMed ID: 26614007)
1. A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks.
Mohri D; Ijichi H; Miyabayashi K; Takahashi R; Kudo Y; Sasaki T; Asaoka Y; Tanaka Y; Ikenoue T; Tateishi K; Tada M; Isayama H; Koike K
J Gastroenterol; 2016 Jul; 51(7):711-21. PubMed ID: 26614007
[TBL] [Abstract][Full Text] [Related]
2. SNORA74B gene silencing inhibits gallbladder cancer cells by inducing PHLPP and suppressing Akt/mTOR signaling.
Qin Y; Meng L; Fu Y; Quan Z; Ma M; Weng M; Zhang Z; Gao C; Shi X; Han K
Oncotarget; 2017 Mar; 8(12):19980-19996. PubMed ID: 28212545
[TBL] [Abstract][Full Text] [Related]
3. Fibronectin promotes cell proliferation and invasion through mTOR signaling pathway activation in gallbladder cancer.
Cao Y; Liu X; Lu W; Chen Y; Wu X; Li M; Wang XA; Zhang F; Jiang L; Zhang Y; Hu Y; Xiang S; Shu Y; Bao R; Li H; Wu W; Weng H; Yen Y; Liu Y
Cancer Lett; 2015 May; 360(2):141-50. PubMed ID: 25657110
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
5. Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing.
Li M; Chen L; Qu Y; Sui F; Yang Q; Ji M; Shi B; Chen M; Hou P
Oncotarget; 2017 May; 8(22):36319-36330. PubMed ID: 28422736
[TBL] [Abstract][Full Text] [Related]
6. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
7. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
Kuger S; Flentje M; Djuzenova CS
Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
[TBL] [Abstract][Full Text] [Related]
9. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
10. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
[TBL] [Abstract][Full Text] [Related]
11. C24-Ceramide Drives Gallbladder Cancer Progression Through Directly Targeting Phosphatidylinositol 5-Phosphate 4-Kinase Type-2 Gamma to Facilitate Mammalian Target of Rapamycin Signaling Activation.
Zhang Y; Wang H; Chen T; Wang H; Liang X; Zhang Y; Duan J; Qian S; Qiao K; Zhang L; Liu Y; Wang J
Hepatology; 2021 Feb; 73(2):692-712. PubMed ID: 32374916
[TBL] [Abstract][Full Text] [Related]
12. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
13. The ERK/MAPK pathway is overexpressed and activated in gallbladder cancer.
Buchegger K; Silva R; López J; Ili C; Araya JC; Leal P; Brebi P; Riquelme I; Roa JC
Pathol Res Pract; 2017 May; 213(5):476-482. PubMed ID: 28285962
[TBL] [Abstract][Full Text] [Related]
14. Desulfation of cell surface HSPG is an effective strategy for the treatment of gallbladder carcinoma.
Yi B; Qiu Y; Ji W; Wei M; Liu C; Peng Z; Zhang Y; Quan Z; Tang Z; Su C
Cancer Lett; 2016 Oct; 381(2):349-58. PubMed ID: 27502167
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anti-proliferative effects of mTOR and MEK inhibitors in high-grade chondrosarcoma cell line OUMS-27.
Fukumoto S; Kanbara K; Neo M
Acta Histochem; 2018 Feb; 120(2):142-150. PubMed ID: 29397960
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling.
Zhang P; Guo Z; Wu Y; Hu R; Du J; He X; Jiao X; Zhu X
PLoS One; 2015; 10(8):e0136193. PubMed ID: 26287365
[TBL] [Abstract][Full Text] [Related]
17. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice.
Weber H; Leal P; Stein S; Kunkel H; García P; Bizama C; Espinoza JA; Riquelme I; Nervi B; Araya JC; Grez M; Roa JC
Oncotarget; 2015 Oct; 6(31):31877-88. PubMed ID: 26397134
[TBL] [Abstract][Full Text] [Related]
20. Galectin-9: An anticancer molecule for gallbladder carcinoma.
Tadokoro T; Morishita A; Fujihara S; Iwama H; Niki T; Fujita K; Akashi E; Mimura S; Oura K; Sakamoto T; Nomura T; Tani J; Miyoshi H; Yoneyama H; Himoto T; Hirashima M; Masaki T
Int J Oncol; 2016 Mar; 48(3):1165-74. PubMed ID: 26797414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
